SyntekaBio

SyntekaBio Net Change in Cash

The Net Change in Cash of SyntekaBio (226330.KQ) as of Nov 20, 2026 is 4.28 B KRW. In the previous year, Net Change in Cash was -7.60 B KRW — a change of -156.30% (higher).

Net Change in Cash

4.28 BKRW

YoY

-156.30%

Last updated:

Net Change in Cash of SyntekaBio is 2025 4.28 B KRW. Net Change in Cash of SyntekaBio was 2024 -7.60 B KRW. It decreases by -156.30% higher compared to the previous year.

The SyntekaBio Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
322.66 M KRW
Jan 1, 2019
16.84 B KRW
Jan 1, 2020
-14.57 B KRW
Jan 1, 2021
11.06 B KRW
Jan 1, 2022
21.63 B KRW
Jan 1, 2023
-15.67 B KRW
Jan 1, 2024
-7.60 B KRW
Jan 1, 2025
4.28 B KRW
The SyntekaBio Net Change in Cash history
YEARNet Change in CashYoY
4.28 BKRW-156.30%
-7.60 BKRW-51.50%
-15.67 BKRW-172.45%
21.63 BKRW+95.64%
11.06 BKRW-175.91%
-14.57 BKRW-186.52%
16.84 BKRW+5,117.86%
322.66 MKRW+1,056.46%
27.90 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Net Change in Cash of SyntekaBio is 4.28 B KRW in 2025.

Net Change in Cash of SyntekaBio changed from -7.60 B KRW to 4.28 B KRW, representing a -156.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's SyntekaBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — SyntekaBio

All Key Metrics — SyntekaBio